INV-14AGreenfield
Pharma cluster
- Capital
- $2.40B
- Direct jobs
- 18,000
- Indirect
- 32,000
- IRR target
- 15%
- ROI band
- 13–17%
- Payback
- 9 yr
- Stage
- S2
- ESG
- 86/100
12-year delivery timeline
Feasibility & EIA
Y0.0–Y1.0
Master design
Y1.0–Y2.0
Financing close
Y2.0–Y3.0
Site mobilisation
Y3.0–Y4.0
Vertical construction
Y3.5–Y6.0
Commissioning
Y5.5–Y7.0
Operations & stabilization
Y7.0–Y12.0
Sensitivity · best / base / worst12-yr horizon · 10% discount
| Case | IRR | ROI band | Payback | MOIC | NPV |
|---|---|---|---|---|---|
| worst | -2.1% | -4.1–-0.1% | 12 yr | 0.83× | $-1.75B |
| base | 5.8% | 3.8–7.8% | 10.9 yr | 1.6× | $-612M |
| best | 11.1% | 9.1–13.1% | 7.4 yr | 2.36× | $169M |
Capex variance
1.20×1.00×0.92×
Operating cost variance
1.15×1.00×0.93×
Demand / utilisation
0.80×1.00×1.15×
Exit / terminal value
0.85×1.00×1.20×
FX & macro stability
0.92×1.00×1.05×




